货号:A787534
同义名:
MDP; N-Acetylmuramoyl dipeptide
Muramyl dipeptide是一种合成免疫反应肽,通过诱导Runx2促进骨形成,直接通过MAPK途径上调Runx2基因表达来增强成骨细胞分化,间接通过降低RANKL/OPG比率来减弱破骨细胞分化。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | p38 MAPK ↓ ↑ | p38α ↓ ↑ | p38β ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMS-582949 |
+++
p38 MAPK, IC50: 13 nM |
98% | |||||||||||||||||
Adezmapimod | 99%+ | ||||||||||||||||||
Pexmetinib | ✔ | Tie-2 | 99%+ | ||||||||||||||||
Skepinone-L |
++++
p38α, IC50: 5 nM |
98% | |||||||||||||||||
Doramapimod |
++++
p38α, IC50: 38 nM p38α, Kd: 0.1 nM |
99%+ | |||||||||||||||||
VX-702 | 99%+ | ||||||||||||||||||
Ralimetinib dimesylate |
++++
p38α, IC50: 7 nM |
98% | |||||||||||||||||
SB 202190 |
++
p38α, IC50: 50 nM |
++
p38β, IC50: 100 nM |
99%+ | ||||||||||||||||
Losmapimod |
++++
p38α, pKi: 8.1 |
+++
p38β, pKi: 7.6 |
99%+ | ||||||||||||||||
Neflamapimod |
+++
p38α, IC50: 10 nM |
+
p38β, IC50: 220 nM |
99%+ | ||||||||||||||||
PH-797804 |
++
p38α, IC50: 26 nM |
+
p38β, IC50: 102 nM |
99% | ||||||||||||||||
TAK-715 |
++++
p38α, IC50: 7.1 nM |
+
p38β, IC50: 0.20 μM |
99%+ | ||||||||||||||||
SB 239063 |
++
p38α, IC50: 44 nM |
++
p38β, IC50: 44 nM |
99%+ | ||||||||||||||||
Pamapimod |
+++
p38α, IC50: 0.014 μM |
+
p38β, IC50: 0.48 μM |
98%+ | ||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
Concentration | Treated Time | Description | References | |
rat costal chondrocytes | 0.05-50 μg/ml | 72 h | No effect on glycosaminoglycan synthesis when used alone, but enhanced the lipopolysaccharide-induced inhibition of glycosaminoglycan synthesis when co-administered with lipopolysaccharide | Ann Rheum Dis. 1993 Jan;52(1):32-6. |
murine bone marrow-derived dendritic cells | 50 μg/ml | 24 h | To validate the effect of MDP prestimulation in murine BMDCs, showing that NOD2-intact BMDCs exhibited reduced responsiveness to TLR2, TLR4, TLR5, and TLR9 ligands after MDP prestimulation, while NOD2-deficient BMDCs did not. | J Clin Invest. 2008 Feb;118(2):545-59. |
human monocyte-derived dendritic cells | 10 μg/ml | 24 h | To investigate the effect of MDP prestimulation on subsequent TLR ligand-induced cytokine responses, showing that MDP prestimulation reduced proinflammatory cytokine production (e.g., IL-12p40, IL-6, and CXCL10) in response to multiple TLR ligands. | J Clin Invest. 2008 Feb;118(2):545-59. |
J774.1 macrophage-like cell line | 1 μM | 4 h | Significantly enhanced the superoxide anion production capacity upon PMA stimulation. | J Exp Med. 1980 Jan 1;151(1):101-14. |
mouse peritoneal macrophages | 1 μM | overnight | Enhanced the ability of macrophages to produce superoxide anion in response to PMA stimulation, with a release twice that of control cells. | J Exp Med. 1980 Jan 1;151(1):101-14. |
Mouse bone marrow-derived macrophages (BMMs) | 3 or 10 µg/ml | 24 h | To evaluate the effect of MDP on SaLTA-induced NO production. Results showed that MDP significantly enhanced SaLTA-induced NO production, and this enhancement was attenuated in BMMs from TLR2-, CD14-, MyD88-, and NOD2-deficient mice. | Front Immunol. 2024 Dec 6;15:1451315. |
RAW 264.7 cells | 3 or 10 µg/ml | 24 h | To evaluate the effect of MDP on SaLTA-induced NO production. Results showed that MDP alone did not affect NO production but significantly enhanced SaLTA-induced NO production. | Front Immunol. 2024 Dec 6;15:1451315. |
human dental pulp cells (HDPCs) | 1-20 µg/mL | 14 days | MDP significantly inhibited odontoblast differentiation of HDPCs, as shown by reduced ALP activity, decreased expression of odontoblast/osteoblast markers, and diminished mineralized nodule formation. NOD2 siRNA transfection reversed the MDP-downregulated odontoblast differentiation. | J Dent Res. 2014 Jul;93(7):678-84. |
THP-1 cells | 50 µg/mL | 24 h | MDP induced a significant dose-dependent increase in IL-6 and TNFα secretion upon re-stimulation with LPS or Pam3Cys, indicating that MDP can induce a trained immunity phenotype. | Front Immunol. 2022 Jul 4;13:840751. |
HEK-Blue™-hNOD2 cells | 0.1, 0.2, 0.4, 1, 5, 10 μg/mL | 6 h | To evaluate the activation of NOD2 receptor by MDP, results showed that MDP's effect is dose-dependent, with the best induction at 8 μg/mL. | Cells. 2022 Jul 19;11(14):2241. |
Administration | Dosage | Frequency | Description | References | ||
Mice | TNBS-induced colitis | Intraperitoneal injection | 100 μg | 3 consecutive days (days –3 to –1) | To evaluate the protective effect of MDP pretreatment on TNBS colitis, showing that MDP pretreatment significantly reduced weight loss and histopathological damage and decreased cytokine responses to multiple TLR ligands in MLN and colonic LP cells. | J Clin Invest. 2008 Feb;118(2):545-59. |
Mice | Mouse model of Alzheimer's disease | Intraperitoneal injection | 10 mg/kg | High frequency (2 times/week over 6 months) and low frequency (once a week over 3 months) | To evaluate the effects of MDP on cognitive function in a mouse model of Alzheimer's disease. Results showed that MDP improved memory function, increased expression of synaptic plasticity marker PSD95 and Aβ clearance protein LRP1, increased monocyte chemoattractant protein-1 (MCP-1) levels, decreased intercellular adhesion molecule-1 (ICAM-1) levels, but did not alter microglial marker Iba1 expression. | J Neuroinflammation. 2020 Jul 22;17(1):218 |
Mice | APP swe/PS1 mouse model | Intraperitoneal injection | 10 mg/kg | Once daily for 3 consecutive days, then once a week for 3 months | To study the effect of MDP on cognitive decline and Alzheimer's disease pathology in APP swe/PS1 mice. Results showed that MDP injections delayed cognitive decline, protected the blood-brain barrier, and reduced amyloid load through different mechanisms in different sexes. | Cells. 2022 Jul 19;11(14):2241. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.03mL 0.41mL 0.20mL |
10.15mL 2.03mL 1.02mL |
20.31mL 4.06mL 2.03mL |
CAS号 | 53678-77-6 |
分子式 | C19H32N4O11 |
分子量 | 492.48 |
SMILES Code | [C@H]([C@@H](NC(C)=O)C=O)(O[C@@H](C(N[C@H](C(N[C@H](CCC(O)=O)C(N)=O)=O)C)=O)C)[C@@H]([C@@H](CO)O)O |
MDL No. | MFCD00077638 |
别名 | MDP; N-Acetylmuramoyl dipeptide; N-Acetylmuramyl-L-alanyl-D-isoglutamine; Ac-muramyl-Ala-D-Glu-NH2; Adjuvant Peptide |
运输 | 蓝冰 |
存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C |
溶解方案 |
DMSO: 105 mg/mL(213.21 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 50 mg/mL(101.53 mM),配合低频超声助溶 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|